Reset Map6 Results
2-26-1, Muraoka-higashi, Shonan-iPark Fujisawa-city, Kanagawa, 2518555 JapanRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
Shonan Health Innovation Park, 2-26-1, Muraoka-Higashi Fujisawa, Kanagawa, 251-8555 JapanRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
855 N. Wolfe St., Suite 631 Baltimore, MD, 21205 United StatesRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
855 N. Wolfe St., Suite 631 Baltimore, Maryland, 21205 United StatesRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
Rm 409, Life Innovation Center 3-25-22, Tonomachi, Kawasaki-ku Kawasaki, Kanagawa, 210-0821 JapanRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
855 N Wolfe St Suite 631 Baltimore, MD, 21205 1503 United StatesRicoh Biosciences accelerates drug discovery and cell therapy development with ready-to-use, functional human iPSC-derived cell models, differentiation kits, and tailored CRO services—helping teams generate relevant biological data in as little as 1–2 weeks. Our proprietary Quick-Tissue platform uses transcription factor differentiation to create specialized cell types from induced pluripotent stem cells (iPSCs) without conventional lengthy differentiation workflows. Built on non-integrating, Sendai or mRNA-based reprogramming approaches, Quick-Tissue enables rapid, scalable generation of functional human cells for disease modeling, compound profiling, target validation, mechanism-of-action studies, and safety assessment. Ricoh Biosciences provides iPSC-derived neurons spanning excitatory, GABAergic, cholinergic, motor, dopaminergic, and sensory phenotypes, with additional cell lineages in development. We also offer custom cell models generated from healthy donor and disease-specific iPSC lines, supporting programs in neurodegeneration and other complex human diseases. Our disease-modeling capabilities include applications relevant to Alzheimer’s disease, ALS, and Parkinson’s disease. Our drug discovery CRO services combine physiologically relevant human cells with functional readouts, including calcium flux assay services using FDSS-based platforms; MEA electrophysiology using Axion Maestro and MaxWell systems in 24-, 48-, and 96-well formats; and customized phenotypic assays. These capabilities support early discovery through translational research, including neurotoxicity assessment, efficacy profiling, patient-relevant disease models, and data generation that can inform regulatory submissions. Our human iPSC-derived cell models also serve as physiologically relevant New Approach Methodologies (NAMs) for programs seeking non-animal alternatives for toxicology and efficacy assessment. Located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland, Ricoh Biosciences partners with pharmaceutical and biotechnology teams seeking fast, flexible access to robust iPSC and induced pluripotent stem cell solutions. Our Research Use Only products require no MTA or license, making it straightforward to begin evaluating the right model for your program. Contact Ricoh Biosciences to discuss custom iPSC differentiation, functional assay development, or a disease-relevant human cell model for your next program.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.